Start With EYLEA. Stay With EYLEA.

The dosing schedules of EYLEA are shown in the context of visual acuity outcomes and mean number of injections according to clinical trial data.1-5 EYLEA offers flexible dosing options for certain approved indications in a single 2 mg formulation.1

Around 5.7 million doeses since launch. Around 635,000 eyes treated with EYLEA since launch. Around 5.7 million doeses since launch. Around 635,000 eyes treated with EYLEA since launch.

Dosing Driving Efficacy Outcomes Across All Indications1-5

1 Year (52 weeks) Wet AMD. 1 Year (52 weeks) DME. 2 Year (100 weeks) DME and DR in Patients with DME. 6 Months (24 weeks) Macular Edema following RVO. 1 Year (52 weeks) Wet AMD. 1 Year (52 weeks) DME. 2 Year (100 weeks) DME and DR in Patients with DME. 6 Months (24 weeks) Macular Edema following RVO.

EYLEA 2 mg Dosing Flexibility for Certain Approved Indications: Options for Your Patients' Individual Needs1

EYLEA dosing schedule for Wet AMD, DME, DR in DME, and Macular Edema following RVO. EYLEA dosing schedule for Wet AMD, DME, DR in DME, and Macular Edema following RVO.
Clinical Practice Information on Injection Administration and Injection Frequency/Outcomes
  • Injection Preparation and Administration

    9:55
  • Wet AMD Consistent Dosing With EYLEA

    6:36
  • DME Consistent Dosing With EYLEA

    6:58
Reimbursement Support

Get help navigating the
reimbursement process. Find enrollment forms, sample appeal letters, and more.

See the details
Patient Support

We're committed to help ensure
your eligible patients have access to EYLEA regardless of insurance or coverage.

Find support
News

Keep up to date on
current EYLEA clinical information,
events, and more.

Read the latest
Important Safety Information and Indications
  • EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in patients with DME.

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. August 2018.
  2. Heier JS, Brown DM, Chong V, et al; for the VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
  3. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration. Ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201.
  4. Khurana R. Extended injection interval (≥q12 wks) maintains vision in neovascular age-related macular degeneration: year 2 VIEW subanalysis. Poster presented at: American Academy of Ophthalmology Annual Meeting; November 11-14, 2017; New Orleans, LA.
  5. Data on file. Regeneron Pharmaceuticals, Inc.